- Evaluation of sotorasib (i.e., administered orally at 960 mg once daily) in patients with advanced or metastatic KRAS G12C mutated NSCLC, previously treated with systemic therapy (i.e., ≤3 previous lines of systemic therapy). Here, KRAS is linked to non-small cell lung carcinoma.